A Phase 2 Study of Leflunomide in African-American and European-American People with High-Risk Smoldering Multiple Myeloma

Full Title

Phase 2 Trial of Leflunomide in African-American and European-American Patients with High-Risk Smoldering Multiple Myeloma (WIRB)

Purpose

Smoldering myeloma is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms. In this study, researchers want to see if leflunomide can delay multiple myeloma symptoms. It is being assessed in African-American and European-American people with smoldering multiple myeloma that has a high chance of getting worse. Leflunomide is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have smoldering multiple myeloma with a high chance of getting worse.
• Be African American or European American.
• Not have had prior treatment for multiple myeloma.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please contact Dr. Saad Usmani’s office at 646-608-4165.